Abbott received marketing authorization from the European Commission for the use of Humira as a treatment for severe Crohn’s disease. Humira is the first self-administered biologic for the treatment of Crohn’s disease, offering a convenient treatment option that can help patients control of their disease. This is the fourth indication for Humira in the U.S. and the EU.

Crohn’s disease is a chronic, inflammatory disease of the gastrointestinal (GI) tract that affects more than one million people in North America and Europe. Common symptoms of Crohn’s disease include diarrhea, cramping, abdominal pain, weight loss, fever, and in some cases, rectal bleeding. Complications include intestinal obstruction, ulcers that form tunnels to surrounding tissues, and malnutrition.